If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). Understanding what this warning means in practical terms—before and after treatment—is essential for making informed decisions. The legacy of medical knowledge has long guided patients through complex treatment risks, and this page provides a clear timeline of PML risk factors and monitoring steps.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, to communicate this risk. Clinical presentation and diagnosis of PML involve a range of neurological symptoms that can include progressive weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is typically confirmed through brain imaging, such as MRI, and detection of JCV DNA in cerebrospinal fluid. In a large retrospective cohort study of 456 PML cases observed between 1987 and 2024, researchers described the demographic, clinical, radiological, and laboratory characteristics of the disease, noting that PML is a severe demyelinating condition affecting immunocompromised individuals (https://pubmed.ncbi.nlm.nih.gov/40922664/). The study included patients with either a definite or clinico-radiological diagnosis, highlighting the importance of both laboratory and imaging findings in confirming the disease.
The pharmacological mechanism linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri inhibits the migration of immune cells across the blood-brain barrier, reducing inflammation in the central nervous system. However, this immunosuppressive effect also impairs the brain's ability to control JCV, a virus that is latent in many individuals. Under normal immune surveillance, JCV replication is suppressed. With Tysabri treatment, the reduced immune cell trafficking allows JCV to reactivate and infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The FDA label identifies three specific risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. Reported adverse effects from clinical trials include PML occurring in three patients who received Tysabri. Two cases were observed among 1,869 patients with multiple sclerosis treated for a median of 120 weeks, and these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore that PML can develop even with relatively short exposure, though risk increases with longer treatment.
The adequacy of warnings regarding Tysabri and PML is a critical consideration for affected patients. The FDA boxed warning explicitly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also mandates that healthcare professionals monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first indication. Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients and providers are aware of the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether the warnings were sufficiently communicated to patients prior to treatment initiation, particularly in cases where PML developed. Settlement-related considerations for affected patients involve the timeline between Tysabri exposure and documented harm. PML can develop months to years after starting Tysabri, with risk increasing after two years of therapy. The clinical trials documented PML cases at varying intervals, including after eight doses and after a median of 120 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML, the consequences are often devastating, leading to permanent neurological deficits or death. Legal claims may focus on whether the manufacturer provided adequate warnings about the risk, whether the TOUCH program was properly implemented, and whether the patient's specific risk factors (such as anti-JCV antibody status) were appropriately considered. In Pennsylvania, as in other jurisdictions, affected individuals may seek compensation for medical expenses, lost income, pain and suffering, and other damages through product liability or failure-to-warn lawsuits.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The three main risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Yes, a Pennsylvania Tysabri PML injury lawyer can assist affected individuals in seeking compensation for medical expenses, lost income, and pain and suffering through product liability or failure-to-warn claims.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.